Clinical Trials >> Hypertension with Overweight/Obesity (Starts October 2026):
Hypertension with Overweight/Obesity (Starts October 2026):
Uncontrolled hypertension represents a clear unmet medical need in a population with obesity, such that in the 2025 guidelines, the American Heart Association and the American College of Cardiology recommended considering drugs for treating obesity, like GLP-1 receptor agonists.
The purpose of this clinical research trial is to compare the efficacy and safety of investigational trial medications and placebo in participants with hypertension and obesity with or without type 2 diabetes, regardless of whether they have a hypertension diagnosis or take antihypertensive medication at baseline.
This trial is approximately 42 weeks with up to 15 visits. The investigational trial medication is an injection.
A few qualifications to participate are:
- Age 18 – 75 years old
- BMI ≥ 30 kg
- Resting in-office Systolic Blood Pressure of 130-160
- No weight loss medications in the last 90 days
Qualified participants will:
- See a physician at no cost
- Receive pertinent tests at no cost
- Receive compensation for time and travel
- web design by teaminhouse